Geode Capital Management LLC Sells 56,596 Shares of United Therapeutics Corporation $UTHR

Geode Capital Management LLC trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR) by 4.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,193,064 shares of the biotechnology company’s stock after selling 56,596 shares during the period. Geode Capital Management LLC’s holdings in United Therapeutics were worth $580,238,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in UTHR. Torren Management LLC bought a new stake in United Therapeutics in the 4th quarter worth about $26,000. Activest Wealth Management boosted its stake in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC boosted its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new position in United Therapeutics in the fourth quarter valued at about $31,000. 94.08% of the stock is owned by institutional investors.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is still drawing support from bullish analyst coverage, including recent higher price targets and buy/overweight ratings, which suggests Wall Street remains constructive on the long-term outlook.
• Positive Sentiment: The company continues to highlight clinical and business-development catalysts, including its PHINDER screening study, xenokidney/EXTEND trial progress, and a planned presentation at the Jefferies Global Healthcare Conference, all of which help keep the growth story visible to investors. Article Title Article Title
• Neutral Sentiment: A separate article referenced United Therapeutics in a broader mid-cap stock discussion, but it did not appear to contain company-specific new information likely to move the stock.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares and CFO James Edgemond sold 10,000 shares this week. Multiple insider sales can weigh on sentiment, especially when they come soon after a disappointing earnings report. Article Title Article Title
• Negative Sentiment: The company’s most recent quarterly results missed estimates on both EPS and revenue, leaving investors with an ongoing fundamental overhang despite strong profitability metrics.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on UTHR. UBS Group boosted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Cantor Fitzgerald boosted their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Royal Bank Of Canada cut their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, HC Wainwright boosted their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This represents a 34.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders have sold 601,473 shares of company stock valued at $337,090,644. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $556.82 on Friday. The company’s fifty day moving average price is $566.51 and its 200-day moving average price is $515.84. The firm has a market capitalization of $23.64 billion, a price-to-earnings ratio of 20.55, a PEG ratio of 1.81 and a beta of 0.60. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the company earned $6.63 EPS. As a group, equities research analysts expect that United Therapeutics Corporation will post 26.92 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.